Remmel H. Lawrence 4

What Happened
Remmel H. Lawrence, a director of Atossa Therapeutics, was granted 10,000 restricted stock units (RSUs) on May 12, 2026. The units were awarded at $0.00 per share (no cash purchase) and represent a contingent right to receive one share of common stock per RSU upon vesting.

Key Details

• Transaction type: Award/Grant (Form 4 code A) of 10,000 RSUs.
• Transaction date: May 12, 2026; Form 4 filed May 14, 2026 (timely).
• Price: $0.00 per RSU (no upfront cash paid). Total reported acquisition value: $0.
• Vesting: RSUs vest on the first anniversary of May 12, 2026 (i.e., May 12, 2027).
• Shares owned after transaction: Not specified in the filing.
• Footnote: Each RSU converts to one share upon vesting. No tax withholding or sale noted in the filing.

Context
RSU grants to directors are a common form of equity compensation aimed at aligning long-term interests with shareholders; they do not represent immediate ownership until they vest. This was an award, not a market purchase or sale, so it does not reflect an immediate buy/sell sentiment.